4894 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Cuorips, Inc. engages in the development and commercialization of induced pluripotent stem cells (iPS) derived cardiomyocyte sheets. It handles research, development, manufacture, and sales of cellular and tissue-based products and cell processing products. The firm also offers contract development and manufacturing services and consulting services of cellular and tissue-based products and cell processing products. The company was founded on March 21, 2017 and is headquartered in Tokyo, Japan.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
4894 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company